uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting
October 24, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 24, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs
October 05, 2023 07:05 ET
|
uniQure Inc.
~ Reduction of 28% of workforce not related to HEMGENIX® manufacturing obligations; Total cost savings of $180 million to extend cash runway into second quarter of 2027 ~ ~ Discontinuing investments...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, Oct. 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 01, 2023 07:05 ET
|
uniQure Inc.
~ Announced encouraging interim analysis data from ongoing Phase I/II clinical trial of AMT-130 in Huntington’s disease showing preservation of function compared to baseline and clinical benefits...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 16, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million
May 15, 2023 07:05 ET
|
uniQure Inc.
~ uniQure to receive $375 million upfront cash payment ~ ~ Under the existing agreement with CSL Behring, uniQure retains the rights to future milestones totaling up to $1.5 billion and maintains an...
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
May 09, 2023 07:05 ET
|
uniQure Inc.
~ Clinical update from U.S. Phase I/II trial in Huntington’s disease expected in second quarter 2023 ~ ~ Continued progress towards initiating two new Phase I/II clinical studies for AMT-260 in...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 13, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...
uniQure to Participate in Multiple Upcoming Industry Conferences in March
March 02, 2023 07:05 ET
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, March 02, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with...